These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 2698926)

  • 1. Do weak mineralocorticoids affect the pathogenesis of hypertension in Cushing's disease?
    Hermus A; Hobma S; Pieters G; Benraad T; Smals A; Kloppenborg P
    J Hypertens Suppl; 1989 Dec; 7(6):S208-9. PubMed ID: 2698926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogenetic aspects of hypertension in Cushing's syndrome.
    Tenschert W; Baumgart P; Greminger P; Vetter W; Vetter H
    Cardiology; 1985; 72 Suppl 1():84-90. PubMed ID: 3902234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid increase of mineralocorticoids after furosemide in low-renin essential hypertension: evidence for 18-hydroxycorticosterone to be a better marker than aldosterone.
    Witzgall H; Thayil G; Weber PC
    Klin Wochenschr; 1982 Aug; 60(16):847-52. PubMed ID: 6752560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cushing's disease: evaluation of mineralocorticoid-induced hypertension.
    Yasuda G; Shionoiri H; Hayashi S; Umemura S; Ikeda Y; Ishii M
    Intern Med; 1993 Oct; 32(10):784-8. PubMed ID: 8012073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circadian secretion of ACTH, cortisol, and mineralocorticoids in Cushing's syndrome.
    Boscaro M; Scaroni C; Masarotto P; Ridolfi P; Benato M; Mantero F
    Clin Exp Hypertens A; 1982; 4(9-10):1779-94. PubMed ID: 6291816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variant of pre-clinical Cushing's syndrome: hypertension and hypokalemia associated with normoreninemic normoaldosteronism.
    Yamakita N; Murai T; Miyamoto K; Matsunami H; Ikeda T; Sasano H; Mune T; Yasuda K
    Hypertens Res; 2002 Jul; 25(4):623-30. PubMed ID: 12358151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma renin activity and urinary aldosterone in Cushing's syndrome.
    Mantero F; Armanini D; Boscaro M
    Horm Metab Res; 1978 Jan; 10(1):65-71. PubMed ID: 204567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of saralasin (1sar-8-ala-angiotensin II) on blood pressure in patients with Cushing's syndrome.
    Vetter W; Vetter H; Beckerhoff R; Redlich B; Cottier P; Siegenthaler W
    Klin Wochenschr; 1976 Jul; 54(14):661-3. PubMed ID: 979066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple factors contribute to the pathogenesis of hypertension in Cushing's syndrome.
    Saruta T; Suzuki H; Handa M; Igarashi Y; Kondo K; Senba S
    J Clin Endocrinol Metab; 1986 Feb; 62(2):275-9. PubMed ID: 3510223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Markers of vascular function in hypertension due to Cushing's syndrome.
    Zacharieva S; Atanassova I; Nachev E; Orbetzova M; Kirilov G; Kalinov K; Shigarminova R
    Horm Metab Res; 2005 Jan; 37(1):36-9. PubMed ID: 15702437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mineralocorticoid function of the adrenal cortex and the renin--angiotensin system in Itsenko-Cushing's disease].
    Slavnov VN; Luchitskii EV; Komissarenko IV; Cheban AK; Iakovlev AA
    Probl Endokrinol (Mosk); 1978; 24(5):39-44. PubMed ID: 704555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldosterone and other mineralocorticoids in Bartter's syndrome.
    Saruta T; Fujimaki M; Senba S; Saito I; Konishi K
    J Lab Clin Med; 1984 Jun; 103(6):848-53. PubMed ID: 6373989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Captopril in Cushing's syndrome.
    Greminger P; Vetter W; Groth H; Lüscher T; Tenschert W; Siegenthaler W; Vetter H
    Klin Wochenschr; 1984 Sep; 62(18):855-8. PubMed ID: 6387264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case of Cushing's syndrome due to ACTH-independent bilateral macronodular hyperplasia associated with excessive secretion of mineralocorticoids.
    Hayashi Y; Takeda Y; Kaneko K; Koyama H; Aiba M; Ikeda U; Shimada K
    Endocr J; 1998 Aug; 45(4):485-91. PubMed ID: 9881897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pathogenesis of the arterial hypertensive syndrome in Itsenko-Cushing disease].
    Komissarenko IV; Slavnov VN; Cheban AK; Iakovlev AA; Demchenko NP
    Probl Endokrinol (Mosk); 1982; 28(6):28-31. PubMed ID: 6296809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basal and saline-stimulated plasma atrial natriuretic hormone in Cushing's syndrome.
    McKnight JA; McCance DR; Roberts G; Sheridan B; Atkinson AB
    Acta Endocrinol (Copenh); 1991 Jan; 124(1):7-11. PubMed ID: 1825738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypertension and aldosterone overproduction without renin suppression in Cushing's syndrome from an adrenal adenoma.
    Guthrie GP; Kotchen TA
    Am J Med; 1979 Sep; 67(3):524-8. PubMed ID: 474601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The changes in renin-angiotensin-aldosterone-system in different subtypes of Cushing's syndrome].
    Cui J; Dou J; Yang G; Zang L; Jin N; Chen K; Du J; Gu W; Wang X; Yang L; Lyu Z; Ba J; Mu Y; Lu J; Li J; Pan C
    Zhonghua Nei Ke Za Zhi; 2015 Jul; 54(7):618-22. PubMed ID: 26359025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hypertension and Cushing's disease].
    Luton JP; Vidal-Trecan G; Mouveroux F; Bricaire H
    Ann Med Interne (Paris); 1983; 134(3):203-8. PubMed ID: 6625411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical manifestation of adrenocorticotropin-determined plasma concentrations of mineralocorticoid hormones.
    Biglieri EG; Brust N; Chang B; Hirai J; Wajchenberg BL; Schambelan M
    Prog Biochem Pharmacol; 1980; 17():36-43. PubMed ID: 6259660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.